{
    "nctId": "NCT02725541",
    "briefTitle": "Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer",
    "officialTitle": "Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Objective response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female gender;\n* Age \u226518 years;\n* Eastern Cooperative Oncology Group performance status of 0-1;\n* Histologically confirmed invasive breast cancer;\n* Primary tumor greater than or equal to 1 cm diameter, as measured by clinical examination and mammography or ultrasound;\n* Any N;\n* No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);\n* HER2 low or equivocal status in the invasive component of the primary tumor (confirmed by a central certified laboratory prior to study entry)\n\n  * HER2 low expression: 1+/2+ by immunohistochemistry and/or HER2/CEP17 ratio \\<2.0 with HER2 copy number \\<6.0 signals/cell\n  * HER2 equivocal expression: HER2 copy number \u22654.0 and \\<6.0 signals/cell;\n* Hematopoietic status:\n\nAbsolute neutrophil count \u2265 1.0 x 10\\^9/L, Platelet count \u2265 100 x 10\\^9/L, Hemoglobin at least 9 g/dL;\n\n\u2022 Hepatic status: Serum total bilirubin \u22641 x upper limit of normal (ULN; In the case of known Gilbert's syndrome, a higher serum total bilirubin \\[\\< 1.5 x ULN\\] is allowed), Aspartate aminotransferase and alanine aminotransferase \u22641.5 x ULN, Alkaline phosphatase \u2264 1.5 x ULN;\n\n\u2022 Renal status: Creatinine \u22641.5 mg/dL;\n\n* International Normalized Ratio \u22641.5 x ULN;\n* Baseline left ventricular ejection fraction \u226550%, as measured by echocardiography or multigated acquisition scan;\n* Negative serum or urine \u03b2-human chorionic gonadotropin pregnancy test within 7 days prior study entry for patients of childbearing potential. Women of childbearing potential must use effective contraception (barrier method \\[condoms, diaphragm\\] in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, and implantable hormonal contraceptives are not allowed) for the duration of the study and for at least 7 months after the last dose of study treatment;\n* Signed informed consent form (ICF);\n* Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol.\n\nExclusion Criteria:\n\n* Previous (less than 5 years) or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and carcinoma in situ of the cervix;\n* Patients with a prior malignancy diagnosed more than 5 years prior to study entry;\n* Preexisting peripheral neuropathy \u2265 grade 2;\n* Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (\u2265180/110), unstable diabetes mellitus, dyspnea at rest, or chronic oxygen therapy;\n* Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical disorder that would interfere with the patient's safety;\n* Unresolved or unstable serious adverse events from prior administration of another investigational drug;\n* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;\n* Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy other than the trial therapy);\n* Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab emtansine or its components;\n* Ejection fraction \\<55% or below the lower limit of the institutional normal range;\n* Pregnant or lactating women;\n* Concomitant use of cytochrome P450 3A4 inhibitors or inducers;\n* Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol;\n* Active infection requiring intravenous or oral antibiotics;\n* Patients unwilling or unable to comply with the protocol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}